ClinicalTrials.gg
CompletedNCT05704725Updated Feb 14, 2025Results posted

A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)

A Phase 3 interventional study of ABP 938 and Aflibercept in Chorioretinal Vascular Disease, sponsored by Amgen. Completed at 4 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-02-14.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

The primary objective of this study is to is to assess the ability of retina specialists to successfully administer, via an intravitreal (IVT) injection, a 2 mg dose of ABP 938, using the ABP 938 aflibercept prefilled syringe (PFS), compared to a 2 mg dose of aflibercept using the aflibercept PFS.

02

Conditions studied

  • Chorioretinal Vascular Disease

Keywords

  • Chorioretinal vascular disease
  • CVD
  • ABP 938
  • EYLEA®
  • aflibercept
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must sign an IRB approved form before any study-specific procedures are initiated.
  • Men or women ≥18 years old.
  • Treatment-naïve or previously treated neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, or diabetic retinopathy in the study eye.

Exclusion criteria

Exclusion Criteria

  • Active intraocular or periocular infection or active intraocular inflammation in either eye.
  • Uncontrolled intraocular pressure greater than (>) 25 mmHg in the study eye.
  • Deemed legally blind in one or both eyes.
  • History of or any current indication of excessive bleeding or recurrent hemorrhages, including any prior excessive intraocular bleeding or hemorrhages after IVT injection or intraocular procedures in either eye.
  • Current systemic infectious disease or on a therapy for active infectious disease.
  • History of any medical, ocular or non-ocular conditions that, in the opinion of the investigator, may interfere with the injection procedure or pose a safety concern.
  • History of stroke or or myocardial infarction within the last 6 months.
  • Treatment with anti-VEGF IVT injection in the study eye within 28 days.
  • Any use of intraocular in the study eye within 3 months.
  • Receipt of any systemic anti-VEGF within the last 6 months.
  • Any invasive intraocular surgery, prior long-acting therapeutic agent, or ocular drug release device implantation in the study eye within the past 3 months.
  • For women: pregnant or breast feeding, or planning to become pregnant while enrolled in the study and for 3 months after IP administration.
  • Sexually active participants and their partners who are of who refuse to use adequate while on-study and for 3 months after IP administration. Male participants must agree not to donate sperm during study and for 3 months following dose of IP.
  • Allergy or to the IP, to any of the of ABP 938 or aflibercept, or to other study-related procedures/medications.
  • Previously enrolled in this study.
  • Participation in any interventional clinical study within 3 months prior to screening.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    ABP 938

    Participants will be randomized in a ratio of 2:1 to receive either a single IVT injection of ABP 938 in a PFS or a single injection of aflibercept in a PFS.

    Drug: ABP 938

  • Experimental
    Aflibercept

    Participants will be randomized in a ratio of 2:1 to receive either a single IVT injection of ABP 938 in a PFS or a single injection of aflibercept in a PFS.

    Drug: Aflibercept

Interventions

  • IVT injection

    Also known as: PAVBLU™

  • IVT injection

    Also known as: Eylea®

06

What researchers measure

Primary outcomes

  1. Percentage of IVT Injections Successfully Administered

    A successful injection was defined by whether the retinal specialist administering the IVT injection answered 'yes' to the following question: Did the PFS allow for the safe and effective administration of the prescribed dose? Percentage of successful injections and Clopper-Pearson 95% Confidence Interval is reported.

    Time frame: Day of IVT injection (study day 1)

Secondary outcomes

  1. Number of Participants With Ocular Treatment Emergent Adverse Events (TEAEs) in Study Eye

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant. Events that met the AE definition are as follows: * Any abnormal or worsening ocular safety result that is considered clinically significant in the medical and scientific judgment of the investigator. * Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition. * New conditions detected or diagnosed after study treatment administration even though it may have been present before the start of the study. * Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a concomitant medication. AEs were classified by system organ class (SOC) according to the Medical Dictionary for Regulatory Activities (medDRA) and graded by Common Terminology Criteria for Adverse Events (CTCAE), version 5.0

    Time frame: Up to 28 days

  2. Number of Participants With Serious Ocular TEAEs in Study Eye

    A serious AE is any event that met at least 1 of the following serious criteria: * Fatal. * Life-threatening (places the participant at immediate risk of death). * Requires inpatient hospitalization or prolongation of existing hospitalization. * Results in persistent or significant disability/incapacity. * Congenital anomaly/birth defect. * Other medically important serious event. AEs were classified by SOC according to medDRA and graded by CTCAE, version 5.0

    Time frame: Up to 28 days

  3. Number of Participants With Non-ocular Serious TEAEs

    A serious AE is any event that met at least 1 of the following serious criteria: * Fatal. * Life-threatening (places the participant at immediate risk of death). * Requires inpatient hospitalization or prolongation of existing hospitalization. * Results in persistent or significant disability/incapacity. * Congenital anomaly/birth defect. * Other medically important serious event. AEs were classified by SOC according to medDRA and graded by CTCAE, version 5.0

    Time frame: Up to 28 days

07

Results

Posted Feb 14, 2025

Participant flow

This study was conducted at 4 centers in the United States between 23 January 2023 and 24 March 2023.

Participant flow — Overall Study
MilestoneABP 938Aflibercept
Started3316
Completed3215
Not completed11
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryPercentage of IVT Injections Successfully Administered

A successful injection was defined by whether the retinal specialist administering the IVT injection answered 'yes' to the following question: Did the PFS allow for the safe and effective administration of the prescribed dose? Percentage of successful injections and Clopper-Pearson 95% Confidence Interval is reported.

Time frame:
Day of IVT injection (study day 1)
Reported as:
Number · Percentage of Successful Injections
Percentage of IVT Injections Successfully Administered
Percentage of Successful InjectionsABP 938Aflibercept
Percentage of IVT Injections Successfully Administered100 (89.1 to 100.0)100 (79.4 to 100.0)
SecondaryNumber of Participants With Ocular Treatment Emergent Adverse Events (TEAEs) in Study Eye

An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant. Events that met the AE definition are as follows: * Any abnormal or worsening ocular safety result that is considered clinically significant in the medical and scientific judgment of the investigator. * Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition. * New conditions detected or diagnosed after study treatment administration even though it may have been present before the start of the study. * Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a concomitant medication. AEs were classified by system organ class (SOC) according to the Medical Dictionary for Regulatory Activities (medDRA) and graded by Common Terminology Criteria for Adverse Events (CTCAE), version 5.0

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Number of Participants With Ocular Treatment Emergent Adverse Events (TEAEs) in Study Eye
ParticipantsABP 938Aflibercept
Number of Participants With Ocular Treatment Emergent Adverse Events (TEAEs) in Study Eye30
SecondaryNumber of Participants With Serious Ocular TEAEs in Study Eye

A serious AE is any event that met at least 1 of the following serious criteria: * Fatal. * Life-threatening (places the participant at immediate risk of death). * Requires inpatient hospitalization or prolongation of existing hospitalization. * Results in persistent or significant disability/incapacity. * Congenital anomaly/birth defect. * Other medically important serious event. AEs were classified by SOC according to medDRA and graded by CTCAE, version 5.0

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Number of Participants With Serious Ocular TEAEs in Study Eye
ParticipantsABP 938Aflibercept
Number of Participants With Serious Ocular TEAEs in Study Eye00
SecondaryNumber of Participants With Non-ocular Serious TEAEs

A serious AE is any event that met at least 1 of the following serious criteria: * Fatal. * Life-threatening (places the participant at immediate risk of death). * Requires inpatient hospitalization or prolongation of existing hospitalization. * Results in persistent or significant disability/incapacity. * Congenital anomaly/birth defect. * Other medically important serious event. AEs were classified by SOC according to medDRA and graded by CTCAE, version 5.0

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Number of Participants With Non-ocular Serious TEAEs
ParticipantsABP 938Aflibercept
Number of Participants With Non-ocular Serious TEAEs00

Adverse events

Collected over 28 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABP 9380/32 (0%)0/32 (0%)2/32 (6.3%)
Aflibercept0/16 (0%)0/16 (0%)2/16 (12.5%)
Most frequent other events
Most frequent other events
EventABP 938Aflibercept
Vitreous detachmentEye disorders2/320/16
DiarrhoeaGastrointestinal disorders0/321/16
ArthralgiaMusculoskeletal and connective tissue disorders0/321/16

Baseline characteristics

Full Analysis Set (FAS): All randomized participants.

Age, Continuous
Age, Continuous(Years)ABP 938AfliberceptTotal
Mean71.0 ± 11.4066.3 ± 15.6469.5 ± 12.97
Sex: Female, Male
Sex: Female, Male(Participants)ABP 938AfliberceptTotal
Female14216
Male191433
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ABP 938AfliberceptTotal
Hispanic or Latino9413
Not Hispanic or Latino231235
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ABP 938AfliberceptTotal
American Indian or Alaska Native112
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American303
White281442
More than one race000
Unknown or Not Reported011
08

Study locations

4 sites
  • Retina Consultants of Texas - Austin Retina
    Austin, Texas 78705, United States
  • Retina Consultants of Texas - Bellaire Retina Center
    Bellaire, Texas 77401, United States
  • Retinal Consultants of Texas - San Antonio Retina Center
    San Antonio, Texas 78240-1657, United States
  • Retina Consultants of Texas - The Woodlands Retina Center
    The Woodlands, Texas 77384, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Feb 2023, 0 months.

Results were first posted in Feb 2025, 1 year 11 months after primary completion. A results delay was requested in Nov 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2023
First posted
Jan 30, 2023
StartActual
Jan 23, 2023
Primary completionActual
Feb 17, 2023
CompletionActual
Mar 24, 2023
Results delay requested
Nov 14, 2023
Results first posted
Feb 14, 2025
Last update
Feb 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05704725
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jan 30, 2023
Start date
Jan 23, 2023
Primary completion
Feb 17, 2023
Completion
Mar 24, 2023
Results posted
Feb 14, 2025
Last update
Feb 14, 2025

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion